# Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes

Study · id `cardio:ct-nct06586203` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06586203](<https://clinicaltrials.gov/study/NCT06586203>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06586203

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2714 participants.

## Technical summary

Registry record NCT06586203. Randomized; double masking; primary purpose prevention. Start 2024-08-23 (actual); primary completion 2027-08-23 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 2714 participants (planned count; ClinicalTrials.gov record NCT06586203, source copy `cardio:ctgov-nct06586203-2024-09-19`, retrieved 2026-10-26)
- Started: 2024-08-23 (actual) (ClinicalTrials.gov record NCT06586203, source copy `cardio:ctgov-nct06586203-2024-09-19`, retrieved 2026-10-26)
- Primary completion: 2027-08-23 (anticipated) (ClinicalTrials.gov record NCT06586203, source copy `cardio:ctgov-nct06586203-2024-09-19`, retrieved 2026-10-26)
- Completion: 2028-08-23 (anticipated) (ClinicalTrials.gov record NCT06586203, source copy `cardio:ctgov-nct06586203-2024-09-19`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT06586203, source copy `cardio:ctgov-nct06586203-2024-09-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06586203-2024-09-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes
- Acronym: GENOCORDIA
- Condition: Diabetes Mellitus, Type 2
- Condition: Cardiovascular Diseases
- Condition: Diabetic Nephropathy Type 2
- Intervention (Device): Polygenic Risk Score
- Lead sponsor: Optithera
- Lead sponsor class: INDUSTRY
- Collaborator: Genome Quebec
- Collaborator class: OTHER
- Collaborator: Genome Canada
- Collaborator class: OTHER
- Collaborator: ELNA Medical
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: bae05092718d7fde7ac3ff40334d60a41ea1ddb5dd7fdca2eb436f55c46fd069
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
